Otsuka Holdings Co., Ltd. (4578) Press Release
Consolidated Financial Results for the Six-Month Period Ended June 30, 2026 [IFRS]
Earlier from Otsuka
- Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2026
- Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
- Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results for VOYXACT in IgAN
- Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT Preserved Kidney Function Over 12 Months in IgA Nephropathy